Tatiana do Nascimento Pedrosa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7185436/publications.pdf

Version: 2024-02-01

25 papers

567 citations

758635 12 h-index 22 g-index

27 all docs

27 docs citations

times ranked

27

881 citing authors

#	Article	IF	CITATIONS
1	Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2. Rheumatology, 2022, 61, 3351-3361.	0.9	13
2	Impact of Distinct Therapies on Antibody Response to <scp>SARSâ€CoV</scp> â€2 Vaccine in Systemic Lupus Erythematosus. Arthritis Care and Research, 2022, 74, 562-571.	1.5	25
3	Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study. Lancet Rheumatology, The, 2022, 4, e113-e124.	2.2	24
4	Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2022, 81, 710-719.	0.5	16
5	Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity. Clinical Rheumatology, 2022, 41, 2079-2089.	1.0	7
6	Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study. Lancet HIV,the, 2022, 9, e323-e331.	2.1	36
7	Hydroxychloroquine blood levels predicts flare in childhood-onset lupus nephritis. Lupus, 2022, 31, 97-104.	0.8	9
8	SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy. Rheumatology, 2022, 61, SI169-SI174.	0.9	9
9	Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial. Annals of the Rheumatic Diseases, 2022, 81, 889-897.	0.5	42
10	Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome. Lupus, 2022, 31, 974-984.	0.8	13
11	The influence of obesity on hydroxychloroquine blood levels in lupus nephritis patients. Lupus, 2021, 30, 554-559.	0.8	14
12	Hydroxychloroquine blood levels in stable lupus nephritis under low dose (2–3 mg/kg/day): 12-month prospective randomized controlled trial. Clinical Rheumatology, 2021, 40, 2745-2751.	1.0	8
13	One-year prospective nerve conduction study of thalidomide neuropathy in lupus erythematosus: Incidence, coasting effect and drug plasma levels. Lupus, 2021, 30, 956-964.	0.8	3
14	Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial. Nature Medicine, 2021, 27, 1744-1751.	15.2	148
15	Influenza A/Singapore (H3N2) component vaccine in systemic lupus erythematosus: A distinct pattern of immunogenicity. Lupus, 2021, 30, 1915-1922.	0.8	3
16	Immunogenicity and safety of primary fractional-dose yellow fever vaccine in autoimmune rheumatic diseases. PLoS Neglected Tropical Diseases, 2021, 15, e0010002.	1.3	5
17	Lupus nephritis-related issues during COVID-19 pandemic quarantine. Lupus, 2020, 29, 1978-1980.	0.8	5
18	Understanding the dynamics of hydroxychloroquine blood levels in lupus nephritis. Lupus, 2020, 29, 560-568.	0.8	18

2

#	Article	IF	CITATIONS
19	A new reconstructed human epidermis for in vitro skin irritation testing. Toxicology in Vitro, 2017, 42, 31-37.	1.1	51
20	In vitro safety and efficacy evaluations of a complex botanical mixture of Eugenia dysenterica DC. (Myrtaceae): Prospects for developing a new dermocosmetic product. Toxicology in Vitro, 2017, 45, 397-408.	1.1	30
21	Methyl-Î ² -cyclodextrin treatment combined to incubation with interleukin-4 reproduces major features of atopic dermatitis in a 3D-culture model. Archives of Dermatological Research, 2017, 309, 63-69.	1.1	16
22	Anti-wrinkle and anti-whitening effects of juc \tilde{A}_i (Libidibia ferrea Mart.) extracts. Archives of Dermatological Research, 2016, 308, 643-654.	1.1	29
23	Ozone Gas as a Benign Sterilization Treatment for PLGA Nanofiber Scaffolds. Tissue Engineering - Part C: Methods, 2016, 22, 338-347.	1.1	21
24	Atividades biol \tilde{A}^3 gicas dos \tilde{A}^3 leos essenciais de Endlicheria citriodora, uma lauraceae rica em geranato de metila. Quimica Nova, 2013, 36, 826-830.	0.3	12
25	Estudo farmacognóstico e atividade in vitro sobre a coagulação sanguÃnea e agregação plaquetária das folhas de Passiflora nitida Kunth (Passifloraceae). Acta Amazonica, 2010, 40, 199-206.	0.3	9